Non-Hodgkin’s lymphoma refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:14:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Non-Hodgkin’s lymphoma refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-of-hsp-car30-immunotherapy-for-patients-with-relapsed-or-refractory-cd30-hodgkin-and-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 15:02:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-hsp-car30-immunotherapy-for-patients-with-relapsed-or-refractory-cd30-hodgkin-and-non-hodgkin-lymphoma/ This clinical trial is focused on studying two types of blood cancers: Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma. These are conditions where the body’s lymphatic system, which is part of the immune system, is affected by cancer. The study is testing a new treatment called HSP-CAR30, which is a type of immunotherapy. Immunotherapy is a treatment that uses the body’s own immune system to fight cancer. In this study, the patient’s own T cells, a type of white blood cell, are modified in the lab to better recognize and attack cancer cells.

The purpose of the study is to evaluate the safety and potential side effects of the HSP-CAR30 treatment. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor participants closely for any side effects or reactions to the treatment. This will help researchers understand how the treatment works and how it affects the body.

In addition to HSP-CAR30, the study involves other medications that may be used in combination with the main treatment. These include Levact (bendamustine hydrochloride), Fludarabina Accord (fludarabine phosphate), Genoxal (cyclophosphamide monohydrate), and RoActemra (tocilizumab). These medications are also given through intravenous infusion and are used to help manage the cancer or support the immune system. The study will continue until the end of 2025, with participants being monitored throughout the process to gather important data on the treatment’s effectiveness and safety.

]]> Study on CD19+ Lymphoid Disease Using Genetically Modified T Cells for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma https://clinicaltrials.eu/trial/study-on-cd19-lymphoid-disease-using-genetically-modified-t-cells-for-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-and-non-hodgkins-lymphoma/ Wed, 29 Apr 2026 14:59:17 +0000 https://clinicaltrials.eu/trial/study-on-cd19-lymphoid-disease-using-genetically-modified-t-cells-for-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-and-non-hodgkins-lymphoma/ This clinical trial is focused on treating patients with certain types of blood cancers, specifically Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL), which have either returned after treatment or have not responded to previous treatments. The study uses a special type of treatment called CD19.CAR T cells, which involves modifying a patient’s own immune cells, known as T lymphocytes, to better recognize and attack cancer cells. These modified cells are then given back to the patient through an infusion, which is a way of delivering medication directly into the bloodstream.

The purpose of the study is to evaluate the safety and feasibility of using these modified T cells in patients with these challenging blood cancers. The study will involve gradually increasing the dose of these cells to find the most effective and safe amount. Patients will receive the treatment and be monitored closely to see how their bodies respond and to check for any side effects. The study aims to understand how well the treatment works in reducing the cancer and improving patient outcomes.

Throughout the study, researchers will assess various aspects, such as the survival and function of the CAR T cells in the body, the reduction of cancer burden, and the overall response of the disease to the treatment. The study will also look at how long the response lasts and the overall survival of patients after receiving the treatment. This research is important for developing new and effective treatments for patients with these difficult-to-treat blood cancers.

]]> Study on the Safety and Effectiveness of Brexucabtagene Autoleucel for Children and Teens with Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-brexucabtagene-autoleucel-for-children-and-teens-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-or-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 14:59:11 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-brexucabtagene-autoleucel-for-children-and-teens-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-or-non-hodgkin-lymphoma/ This clinical trial is focused on studying two types of blood cancers: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia and Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. These are conditions where the cancer has returned or has not responded to previous treatments. The treatment being tested in this study is called KTE-X19, which is a type of cell therapy. This therapy involves using a patient’s own immune cells, which are modified in a laboratory to better recognize and attack cancer cells. The modified cells are then infused back into the patient to help fight the cancer.

The purpose of the study is to evaluate the safety and effectiveness of KTE-X19 in children and adolescents with these types of blood cancers. The study is divided into two phases. In the first phase, the focus is on assessing the safety of the treatment. In the second phase, the study aims to determine how well the treatment works in achieving remission, which means the cancer is no longer detectable. Participants will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study will also look at how long any remission lasts and overall survival rates. This research is important for understanding how effective KTE-X19 is in treating these challenging forms of cancer in young patients.

]]> Study on the Safety and Effects of IPH6501 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-iph6501-for-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 14:30:43 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-iph6501-for-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma/ This clinical trial is focused on studying a type of cancer called Non-Hodgkin Lymphoma, specifically in patients whose disease has returned or not responded to previous treatments. The trial will investigate a new treatment called IPH6501, which is given as a solution through an infusion into the vein. The main goal of the study is to understand how safe and tolerable this new treatment is for patients, and to see if it has any effect on the cancer.

The study will be conducted in two phases. In the first phase, different doses of IPH6501 will be tested to find the safest and most effective dose. In the second phase, the treatment will be given to more patients to further evaluate its safety and potential benefits. Throughout the study, researchers will closely monitor patients for any side effects and how their cancer responds to the treatment.

Participants in this study will have a type of Non-Hodgkin Lymphoma that expresses a protein called CD20. This includes several subtypes of the disease, such as Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. The study aims to provide valuable information about the new treatment, which could help in developing better therapies for this challenging condition in the future.

]]>